TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07911514: A Phase I, Single-Dose, Randomised, Parallel-Group, Open-Label Trial to Assess the Relative Bioavailability of Different Subcutaneous Formulations of AZD9550 and AZD6234 in Participants Living With Overweight or Obesity

Sponsor: AstraZeneca · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 60 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$7,224,320

Rescue Site Savings

+$4,763,536

Unlock Full NCT07911514 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07911514 Rescue Dossier →